既患类风湿关节炎的癌症患者启动免疫检查点抑制剂后的死亡率和免疫相关不良事件:一项回顾性、比较性队列研究
该回顾性比较队列研究在麻省总医院布莱根综合医疗系统和丹娜—法伯癌症研究所开展,纳入2011年4月1日至2021年4月21日启动免疫检查点抑制剂的癌症患者,将87例符合2010年ACR-EULAR标准的既患类风湿关节炎患者与203例非类风湿关节炎对照进行匹配。结果显示两组死亡率无显著差异(校正HR 1.16,95%CI 0.86-1.57,p=0.34),但类风湿关节炎组任何级别免疫相关不良事件风险更高(校正HR 1.72,95%CI 1.20-2.47,p=0.0032),主要归因于轻度类风湿关节炎病情活动。作者认为该类患者可安全接受免疫检查点抑制剂治疗。
要点
- 既患类风湿关节炎患者启动免疫检查点抑制剂后死亡率与匹配对照无显著差异(校正HR 1.16,95%CI 0.86-1.57)。
- 类风湿关节炎组任何级别免疫相关不良事件风险更高(校正HR 1.72,95%CI 1.20-2.47,p=0.0032)。
- 类风湿关节炎组病情活动42例(48%),对照组炎症性关节炎14例(7%)(p<0.0001)。
核心结论
- 既患类风湿关节炎患者启动免疫检查点抑制剂后死亡率和严重免疫相关不良事件风险与匹配对照相似。
- 类风湿关节炎组更易发生免疫相关不良事件,但主要归因于轻度类风湿关节炎病情活动。
- 作者认为该类患者可安全接受免疫检查点抑制剂治疗癌症。
研究设计与样本
- 回顾性、比较性队列研究,在麻省总医院布莱根综合医疗系统和丹娜—法伯癌症研究所开展。
- 检索2011年4月1日至2021年4月21日启动免疫检查点抑制剂的全部个体,共11901例,其中101例符合2010年ACR-EULAR类风湿关节炎标准。
- 将87例既患类风湿关节炎患者按性别、日历年、免疫检查点抑制剂靶点、癌症类型和分期匹配至203例非类风湿关节炎对照。
- 共同主要结局为从索引日期至死亡的时间和至首次免疫相关不良事件的时间,采用校正Cox比例风险模型分析。
主要发现
- 类风湿关节炎组60例(69%)死亡 vs 对照组127例(63%)死亡(校正HR 1.16,95%CI 0.86-1.57;p=0.34)。
- 类风湿关节炎组53例(61%)发生任何级别免疫相关不良事件 vs 对照组99例(49%)(校正HR 1.72,95%CI 1.20-2.47;p=0.0032)。
- 5级免疫相关不良事件(死亡)共2例(1%),均为心肌炎,均发生在对照组。
- 类风湿关节炎组病情活动42例(48%) vs 对照组炎症性关节炎14例(7%)(p<0.0001)。
- 类风湿关节炎组皮疹或皮炎5例(6%) vs 对照组28例(14%)(p=0.048),内分泌病2例(2%) vs 22例(11%)(p=0.0078),结肠炎或肠炎6例(7%) vs 28例(14%)(p=0.094),肝炎3例(3%) vs 19例(9%)(p=0.043)。
关键数值与推荐
- 既患类风湿关节炎须符合2010年ACR-EULAR标准。
- 匹配因素包括性别(记录为男性或女性)、日历年、免疫检查点抑制剂靶点、癌症类型和分期,每例类风湿关节炎患者匹配最多3例对照。
- 免疫相关不良事件的存在、类型和严重程度及类风湿关节炎病情活动由病历回顾确定,死亡通过病历和讣告回顾确认。
临床怎么用
- 原文结论认为既患类风湿关节炎的患者可安全接受免疫检查点抑制剂治疗癌症。
- 原文未据此给出具体的临床推荐或监测方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with pre-existing rheumatoid arthritis initiating immune checkpoint inhibitors for cancer might be at risk of increased mortality, rheumatoid arthritis flares, and other immune-related adverse events (AEs). We aimed to determine whether pre-existing rheumatoid arthritis was associated with higher mortality and immune-related AE risk in patients treated with immune checkpoint inhibitors. METHODS: This retrospective, comparative cohort study was conducted at the Mass General Brigham Integrated Health Care System and the Dana-Farber Cancer Institute in Boston (MA, USA). We searched data repositories to identify all individuals who initiated immune checkpoint inhibitors from April 1, 2011, to April 21, 2021. Patients with pre-existing rheumatoid arthritis had to meet the 2010 American College of Rheumatology-European Alliance of Associations for Rheumatology (ACR-EULAR) criteria. For each pre-existing rheumatoid arthritis case, we matched up to three non-rheumatoid arthritis comparators at the index date of immune checkpoint inhibitor initiation by sex (recorded as male or female), calendar year, immune checkpoint inhibitor target, and cancer type and stage. The coprimary outcomes were time from index date to death and time to the first immune-related AE, measured using an adjusted Cox proportional hazards model. Deaths were identified by medical record and obituary review. Rheumatoid arthritis flares and immune-related AE presence, type, and severity were determined by medical record review. FINDINGS: We identified 11 901 patients who initiated immune checkpoint inhibitors for cancer treatment between April 1, 2011, and April 21, 2021; of those, 101 met the 2010 ACR-EULAR criteria for rheumatoid arthritis. We successfully matched 87 patients with pre-existing rheumatoid arthritis to 203 non-rheumatoid arthritis comparators. The median age was 71·2 years (IQR 63·2-77·1). 178 (61%) of 290 participants were female, 112 (39%) were male and 268 (92%) participants were White. PD-1 was the most common immune checkpoint inhibitor target (80 [92%] of 87 patients with rheumatoid arthritis vs 188 [93%] of 203 comparators). Lung cancer was the most common cancer type (43 [49%] vs 114 [56%]), followed by melanoma (21 [24%] vs 50 [25%]). 60 (69%) patients with rheumatoid arthritis versus 127 (63%) comparators died (adjusted hazard ratio [HR] of 1·16 [95% CI 0·86-1·57]; p=0·34). 53 (61%) patients with rheumatoid arthritis versus 99 (49%) comparators had any all-grade immune-related AE (adjusted HR 1·72 [95% CI 1·20-2·47]; p=0·0032). There were two (1%) grade 5 immune-related AEs (deaths) due to myocarditis, both in the comparator group. Rheumatoid arthritis flares occurred in 42 (48%) patients with rheumatoid arthritis, and inflammatory arthritis occurred in 14 (7%) comparators (p<0·0001). Those with rheumatoid arthritis were less likely to have rash or dermatitis (five [6%] vs 28 [14%]; p=0·048), endocrinopathy (two [2%] vs 22 [11%]; p=0·0078), colitis or enteritis (six [7%] vs 28 [14%] comparators; p=0·094), and hepatitis (three [3%] vs 19 [9%]; p=0·043). INTERPRETATION: Patients with pre-existing rheumatoid arthritis initiating immune checkpoint inhibitors had similar risk of mortality and severe immune-related AEs as matched comparators. Although patients with pre-existing rheumatoid arthritis were more likely to have immune-related AEs, this finding was mostly due to mild rheumatoid arthritis flares. These results suggest that this patient population can safely receive immune checkpoint inhibitors for cancer treatment. FUNDING: None.
引用
- McCarter KR, Wolfgang T, Arabelovic S, et al. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023. PMID: 37841635. doi:10.1016/s2665-9913(23)00064-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。